WO2002022825A3 - The c. albicans tec1 gene (catec1) and the coded tec1p protein - Google Patents

The c. albicans tec1 gene (catec1) and the coded tec1p protein Download PDF

Info

Publication number
WO2002022825A3
WO2002022825A3 PCT/EP2001/010596 EP0110596W WO0222825A3 WO 2002022825 A3 WO2002022825 A3 WO 2002022825A3 EP 0110596 W EP0110596 W EP 0110596W WO 0222825 A3 WO0222825 A3 WO 0222825A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
catec1
albicans
tec1p
tec1
Prior art date
Application number
PCT/EP2001/010596
Other languages
German (de)
French (fr)
Other versions
WO2002022825A2 (en
WO2002022825A9 (en
Inventor
Klaus Schroeppel
Brad N Taylor
Anja Schweizer
Steffen Rupp
Original Assignee
Fraunhofer Ges Forschung
Univ Friedrich Alexander Er
Klaus Schroeppel
Brad N Taylor
Anja Schweizer
Steffen Rupp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10045123A external-priority patent/DE10045123B8/en
Application filed by Fraunhofer Ges Forschung, Univ Friedrich Alexander Er, Klaus Schroeppel, Brad N Taylor, Anja Schweizer, Steffen Rupp filed Critical Fraunhofer Ges Forschung
Priority to EP01984654A priority Critical patent/EP1319075A2/en
Priority to AU2002218175A priority patent/AU2002218175A1/en
Priority to US10/380,334 priority patent/US20040044193A1/en
Publication of WO2002022825A2 publication Critical patent/WO2002022825A2/en
Publication of WO2002022825A9 publication Critical patent/WO2002022825A9/en
Publication of WO2002022825A3 publication Critical patent/WO2002022825A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to nucleotide sequences which code for proteins which modulate the virulence of pathogenic fungal strains, to vectors containing these sequences, to host cells having these nucleotide sequences or these vectors, to proteins which modulate the virulence of pathogenic fungal strains, especially the transcription factor CaTEC1 of Candida albicans, to inhibitors thereof, especially antibodies which target these virulence-modifying proteins, to methods for producing the proteins and inhibitors, to methods for the diagnosis and therapy of diseases which are associated with a Candida infection and to diagnostic and pharmaceutical compositions containing the nucleotide sequences, proteins, host cells and/or antibodies.
PCT/EP2001/010596 2000-09-13 2001-09-13 The c. albicans tec1 gene (catec1) and the coded tec1p protein WO2002022825A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01984654A EP1319075A2 (en) 2000-09-13 2001-09-13 The c. albicans tec1 gene (catec1) and the coded tec1p protein
AU2002218175A AU2002218175A1 (en) 2000-09-13 2001-09-13 The c. albicans tec1 gene (catec1) and the coded tec1p protein
US10/380,334 US20040044193A1 (en) 2000-09-13 2001-09-13 C. albicans tec1 gene (catec1) and the coded tecip protein

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23093600P 2000-09-13 2000-09-13
DE10045123A DE10045123B8 (en) 2000-09-13 2000-09-13 The C. albicans TEC1 GEN (CaTEC1) and the encoded Tec1p protein
US60/230,936 2000-09-13
DE10045123.3 2000-09-13

Publications (3)

Publication Number Publication Date
WO2002022825A2 WO2002022825A2 (en) 2002-03-21
WO2002022825A9 WO2002022825A9 (en) 2002-09-19
WO2002022825A3 true WO2002022825A3 (en) 2002-12-19

Family

ID=26007032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010596 WO2002022825A2 (en) 2000-09-13 2001-09-13 The c. albicans tec1 gene (catec1) and the coded tec1p protein

Country Status (3)

Country Link
EP (1) EP1319075A2 (en)
AU (1) AU2002218175A1 (en)
WO (1) WO2002022825A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028037A1 (en) * 1998-11-10 2000-05-18 Aventis Pharma S.A. CATFIIIA CANDIDA ALBICANS tfIIIA GENE (CatfIIIA) AND THE CODED CATFIIIA PROTEIN

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028037A1 (en) * 1998-11-10 2000-05-18 Aventis Pharma S.A. CATFIIIA CANDIDA ALBICANS tfIIIA GENE (CatfIIIA) AND THE CODED CATFIIIA PROTEIN

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LALOUX I ET AL: "TEC1 A GENE INVOLVED IN THE ACTIVATION OF TY1 AND TY1-MEDIATED GENE EXPRESSION IN SACCHAROMYCES-CEREVISIAE CLONING AND MOLECULAR ANALYSIS", MOLECULAR AND CELLULAR BIOLOGY, vol. 10, no. 7, 1990, pages 3541 - 3550, XP002207862, ISSN: 0270-7306 *
SCHWEIZER ANJA ET AL: "The TEA/ATTS transcription factor CaTec1p regulates hyphal development and virulence in Candida albicans.", MOLECULAR MICROBIOLOGY, vol. 38, no. 3, November 2000 (2000-11-01), pages 435 - 445, XP002207861, ISSN: 0950-382X *

Also Published As

Publication number Publication date
EP1319075A2 (en) 2003-06-18
AU2002218175A1 (en) 2002-03-26
WO2002022825A2 (en) 2002-03-21
WO2002022825A9 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
DE69840333D1 (en) 2-M TRANSITION OF THE CELL CYCLE
EP0826774A3 (en) Staphylococcal Fab I enoyl-ACP reductase
WO2003054012A3 (en) Leptin proteins
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2004087766A3 (en) Peptabody for cancer treatment
WO2002022825A3 (en) The c. albicans tec1 gene (catec1) and the coded tec1p protein
WO2003048317A3 (en) Antibodies to magmas and uses thereof
WO2001057069A3 (en) Targeting peptides
WO2004112575A3 (en) Gene amplification and overexpression in cancer
EP0845535A3 (en) Leader peptidase (lep) from Streptococcus
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO1997040134A3 (en) Human dnase ii
WO2005049793A3 (en) Methods and compositions for combinatorial approaches to cancer gene therapy
WO2006020824A3 (en) Diagnosis and treatment of kawasaki disease and coronavirus infection
AU2001270518A1 (en) Hypha-specific factors from candida albicans
WO2004053117A3 (en) Serine protease
FR2813606B1 (en) TRUNKED PROTEIN BARD1, AND ITS DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
EP1680499B8 (en) Modulation of angiogenesis by bartonella henselae
WO2000026237A3 (en) Chlamydia 98kd putative outer membrane protein and corresponding dna fragments and uses thereof
WO2001049839A3 (en) Method for expressing gene and use thereof
WO2002050116A3 (en) Adhesion molecule protein
WO2002062845A3 (en) Adhesion molecules
AU2015201737B2 (en) Identification of tumour-associated cell surface antigens for diagnosis and therapy
WO2000006743A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 13/13, DRAWINGS, REPLACED BY A NEW PAGE 13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001984654

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001984654

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10380334

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001984654

Country of ref document: EP